Superworth

Spyre Therapeutics EPS SYRE

Diluted earnings per share by quarter and over the last twelve months, from 2015.

Last 12 months, to Jun 30, 2026
−$2.19
Latest quarter, Q2 FY26
−$0.43
Fiscal year 2025
−$2.23

Spyre Therapeutics' earnings per share was −$2.19 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.43.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$2.23n/a
FY2024−$0.09−100%
FY2023$32.06n/a
FY2022−$25.78n/a
FY2021−$25.00n/a
FY2020−$40.25n/a
FY2019−$61.25n/a
FY2018−$52.75n/a
FY2017−$45.25n/a
FY2016−$211.00n/a
FY2015−$477.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.43n/a−$2.19
Q1 FY26−$0.74n/a−$2.37
Q4 FY25−$0.83n/a−$2.23
Q3 FY25−$0.19−118%−$2.42
Q2 FY25−$0.61−203%−$1.17
Q1 FY25−$0.60n/a$0.03
Q4 FY24−$1.02n/a−$0.09
Q3 FY24$1.06+23%−$3.12
Q2 FY24$0.59−99%−$3.32
Q1 FY24−$0.72n/a$36.23
Q4 FY23−$4.05n/a$32.06
Q3 FY23$0.86n/a$31.17

Against its peers

Companies in Drug Manufacturers - General nearest Spyre Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
SYRESpyre Therapeutics−$2.19
TGTXTG Therapeutics$2.74+641% a year
ALKSAlkermes plc.$0.38−82% a year
PTGXProtagonist Therapeutics$1.03+47% a year
CORTCorcept Therapeutics$0.42−63% a year
AMRXAmneal Pharmaceuticals$0.49+4800% a year
LGNDLigand Pharmaceuticals$9.40
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
BMRNBiomarin Pharmaceutical$0.37−89% a year
JAZZJazz Pharmaceuticals$14.62
INDVIndivior Pharmaceuticals$2.78+227% a year
Peer median$1.00

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Spyre Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.